מזומנים למניה אחת abeonatherapeutics.com (ABEO)

Abeona Therapeutics (ABEO) is generating superprofits through monopoly pricing on cell therapy, while orphan drug status blocks the entry of competitors. Cash per share demonstrates liquidity for future projects, while 2.38 records a new level mark. Business stability relies on its own high-tech manufacturing plant in the US, specializing in the treatment of rare pediatric pathologies.
פילוחי מדדים מקיפים ואנליטיקה עבור Abeona Therapeutics, Inc. (ABEO)

The long-term sustainability of Abeona Therapeutics (ABEO) is determined by its ability to fund operating activities without emergency capital raises, which is reflected in this cash per share metric as the weight of liquid assets per security. A decline in this indicator signals a risk of resource shortages, which is critical for Abeona Therapeutics (ABEO) when scaling the commercial launch of the high-cost gene therapy Pz-cel.